LENZ Therapeutics (LENZ) Change in Acquisitions & Divestments (2022 - 2026)

LENZ Therapeutics (LENZ) has reported Change in Acquisitions & Divestments for 5 consecutive years, with $49.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 5.48% year-over-year to $49.2 million; the TTM figure through Mar 2026 stood at $203.1 million (up 66.49% YoY), while the FY2025 annual figure was $206.0 million, up 134.31% from the prior year.
• Change in Acquisitions & Divestments improved to $49.2 million in Q1 2026 per LENZ's latest filing, from $43.3 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $90.0 million in Q3 2022 and bottomed at $1.5 million in Q3 2023.
• Historically, Change in Acquisitions & Divestments has averaged $41.2 million across 5 years, with a median of $43.3 million in 2025.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments plunged 98.33% — and 2024, when it surged 1366.67%.
• LENZ Therapeutics' Change in Acquisitions & Divestments stood at $80.2 million in 2022, then tumbled by 73.83% to $21.0 million in 2023, then soared by 66.19% to $34.9 million in 2024, then advanced by 24.18% to $43.3 million in 2025, then climbed by 13.6% to $49.2 million in 2026.
• Business Quant data shows LENZ's Change in Acquisitions & Divestments at $49.2 million in Q1 2026, $43.3 million in Q4 2025, and $52.4 million in Q3 2025.